Lack of association of indoleamine 2,3-dioxygenase polymorphisms with interferon-alpha-related depression in hepatitis C

Brain, Behavior, and Immunity

Volumn 25, Issue 7, 2011, Pages 1491-1497

  Galvão de Almeida, Amanda ^a,b   Quarantini, Lucas C ^a   Sampaio, Aline S ^c   Lyra, André C ^a   Parise, Carmen Lívia ^b   Paraná, Raymundo ^a   de Oliveira, Irismar R ^a   Koenen, Karestan C ^d   Miranda Scippa, Ângela ^a   Guindalini, Camila ^b  

^a FEDERAL UNIVERSITY OF BAHIA   (Brazil)

^b FEDERAL UNIVERSITY OF SÃO PAULO   (Brazil)

^c UNIVERSITY OF SÃO PAULO   (Brazil)

^d HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

Author keywords

Genetic polymorphism; Hepatitis C; Interferon alpha; Major depressive disorder; Pharmacogenetics; Substance related disorders

Indexed keywords

ALPHA INTERFERON; GENOMIC DNA; INDOLEAMINE 2,3 DIOXYGENASE; RIBAVIRIN;

ADULT; ANTIVIRAL THERAPY; ARTICLE; BRAZIL; CROSS-SECTIONAL STUDY; FEMALE; GENOTYPE; HEPATITIS C; HUMAN; INTERVIEW; MAJOR CLINICAL STUDY; MAJOR DEPRESSION; MALE; MENTAL DISEASE; PATHOPHYSIOLOGY; PHARMACOGENETICS; PRIORITY JOURNAL; SINGLE NUCLEOTIDE POLYMORPHISM;

ADULT; ALLELES; ANTIVIRAL AGENTS; BRAZIL; CROSS-SECTIONAL STUDIES; DEPRESSION; DEPRESSIVE DISORDER; FEMALE; GENETIC ASSOCIATION STUDIES; GENOTYPE; HEPATITIS C; HUMANS; INDOLEAMINE-PYRROLE 2,3,-DIOXYGENASE; INTERFERON-ALPHA; MALE; MIDDLE AGED; POLYMORPHISM, SINGLE NUCLEOTIDE; PSYCHIATRIC STATUS RATING SCALES; RIBAVIRIN;

EID: 80052746416     PISSN: 08891591     EISSN: 10902139     Source Type: Journal    
DOI: 10.1016/j.bbi.2011.06.001     Document Type: Article

References (59)

1. Diagnostical and Statistical Manual of Mental Disorders 1994, American Psychiatric Association, American Psychiatric Press, Washington, DC. fourth ed.
2. Amorim P. Mini International Neuropsychiatric Interview (MINI): validação de entrevista breve para diagnóstico de transtornos mentais. Rev. Bras. Psiquiatr. 2000, 22:106-115.
3. Arefayene M., Philips S., Cao D., Mamidipalli S., Desta Z., Flockhart D.A., Wilkes D.S., Skaar T.C. Identification of genetic variants in the human indoleamine 2, 3-dioxygenase (IDO1) gene, which have altered enzyme activity. Pharmacogenet. Genomics 2009, 19:464-476.
4. Asnis G.M., de La Garza R. Interferon-induced depression in chronic hepatitis C: a review of its prevalence, risk factors, biology, and treatment approaches. J. Clin. Gastroenterol. 2006, 40:322-335.
5. Asnis G.M., de la Garza R., Kohn S.R., Reinus J.F., Henderson M., Shah J. IFN-induced depression: a role for NSAIDs. Psychopharmacol. Bull. 2003, 37:29-50.
6. Batista-Neves S.C., Quarantini L.C., de Almeida A.G., Bressan R.A., Lacerda A.L., de-Oliveira I.R., Paraná R., Miranda-Scippa A. High frequency of unrecognized mental disorders in HCV-infected patients. Gen. Hosp. Psychiatry 2008, 30:80-82.
7. Batista-Neves S., Quarantini L.C., Galvão-de Almeida A., Cardeal M., Lacerda A.L., Paraná R., Reis de-Oliveira I., Bressan R.A., Miranda-Scippa A. Impact of psychiatric disorders on the quality of life of brazilian HCV-infected patients. Braz. J. Infect. Dis. 2009, 13:40-43.
8. Beck A.T., Ward C.H., Mendelson M., Mock J., Erbaugh J. An inventory for measuring depression. Arch. Gen. Psychiatry 1961, 4:561-571.
9. Bedossa P., Poynard T. An algorithm for the grading of activity in chronic hepatitis C. The METAVIR Cooperative Study Group. Hepatology 1996, 24:289-293.
10. Bonaccorso S., Marino V., Puzella A., Pasquini M., Biondi M., Artini M., Almerighi C., Verkerk R., Meltzer H., Maes M. Increased depressive ratings in patients with hepatitis C receiving interferon-alpha-based immunotherapy are related to interferon-alpha-induced changes in the serotonergic system. J. Clin. Psychopharmocol. 2002, 22:86-90.
11. Bonaccorso S., Puzella A., Marino V., Pasquini M., Biondi M., Artini M., Almerighi C., Levrero M., Egyed B., Bosmans E., Meltzer H.Y., Maes M. Immunotherapy with interferon-alpha in patients affected by chronic hepatitis C induces an intercorrelated stimulation of the cytokine network and an increase in depressive and anxiety symptoms. Psychiatry Res. 2001, 105:45-55.
12. Botega N.J., Bio M.R., Zomignani M.A., Garcia Jr.C., Pereira W.A.B. Transtornos de humor em enfermarias de clínica médica e validação de escala de medida (HAD) de ansiedade e depressão. Rev. Saúde. Pública. 1995, 29:355-363.
13. Bull S.J., Huezo-Diaz P., Binder E.B., Cubells J.F., Ranjith G., Maddock C., Miyazaki C., Alexander N., Hotopf M., Cleare A.J., Norris S., Cassidy E., Aitchison K.J., Miller A.H., Pariante C.M. Functional polymorphisms in the interleukin-6 and serotonin transporter genes, and depression and fatigue induced by interferon-alpha and ribavirin treatment. Mol. Psychiatry 2009, 14:1095-1104.
14. Capuron L., Gumnick J.F., Musselman D.L., Lawson D.H., Reemsnyder A., Nemeroff C.B., Miller A.H. Neurobehavioral effects of interferon-alpha in cancer patients: phenomenology and paroxetine responsiveness of symptom dimensions. Neuropsychopharmacology 2002, 26:643-652.
15. Capuron L., Miller A.H. Cytokines and psychopathology: lessons from interferon-alpha. Biol. Psychiatry 2004, 56:819-824.
16. Capuron L., Ravaud A. Prediction of the depressive effects of interferon alfa therapy by the patient's initial affective state. N. Engl. J. Med. 1999, 340:1370.
17. Chen Y., Stankovic R., Cullen K.M., Meininger V., Garner B., Coggan S., Grant R., Brew B.J., Guillemin G.J. The kynurenine pathway and inflammation in amyotrophic lateral sclerosis. Neurotox. Res. 2010, 18:132-142.
18. Comai S., Cavalletto L., Chemello L., Bernardinello E., Ragazzi E., Costa C.V., Bertazzo A. Effects of PEG-interferon alpha plus ribavirin on tryptophan metabolism in patients with chronic hepatitis C. Pharmacol. Res. 2011, 63:85-92.
19. De Bakker P.I., Yelensky R., Pe'er I., Gabriel S.B., Daly M.J., Altshuler D. Efficiency and power in genetic association studies. Nat. Genet. 2005, 37:1217-1223.
20. Dieperink E., Ho S.B., Thuras P., Willenbring M.L. A prospective study of neuropsychiatric symptoms associated with interferon-alpha-2b and ribavirin therapy for patients with chronic hepatitis C. Psychosomatics 2003, 44:104-112.
21. Galvão-de Almeida A., Guindalini C., Batista-Neves S., de Oliveira I.R., Miranda-Scippa A., Quarantini L.C. Can antidepressants prevent interferon-alpha-induced depression? A review of the literature. Gen. Hosp. Psychiatry 2010, 32:401-405.
22. Galvão-de Almeida A., Quarantini L.C., Batista-Neves S., Lyra A.C., Paraná R., de Oliveira I.R., Miranda-Scippa A., Guindalini C. Is the interferon-α-triggered depressive episode a self-limited kind of depression? Four cases of persistent affective symptoms after antiviral treatment in HCV-infected individuals. World J. Biol. Psychiatry 2010, 11:914-918.
23. Gleason O.C., Fucci J.C., Yates W.R., Philipsen M.A. Preventing relapse of major depression during interferon-alpha therapy for hepatitis C-A pilot study. Dig. Dis. Sci. 2007, 52:2557-2563.
24. Gorman J.M. Comorbid depression and anxiety spectrum disorders. Depress Anxiety 1996-1997, 4:160-168.
25. Guindalini C., Howard M., Haddley K., Laranjeira R., Collier D., Ammar N., Craig I., O'Gara C., Bubb V.J., Greenwood T., Kelsoe J., Asherson P., Murray R.M., Castelo A., Quinn J.P., Vallada H., Breen G. A dopamine transporter gene functional variant associated with cocaine abuse in a Brazilian sample. Proc. Natl. Acad. Sci. U. S. A. 2006, 103:4552-4557.
26. Hauser P., Khosla J., Aurora H., Laurin J., Kling M.A., Hill J., Gulati M., Thornton A.J., Schultz R.L., Valentine A.D., Meyers C.A., Howell C.D. A prospective study of the incidence and open-label treatment of interferon-induced major depressive disorder in patients with hepatitis C. Mol. Psychiatry 2002, 7:942-947.
27. Hauser P., Soler R., Reed S., Kane R., Gulati M., Khosla J., Kling M.A., Valentine A.D., Meyers C.A. Prophylactic treatment of depression induced by interferon-alpha. Psychosomatics 2000, 41:439-441.
28. Horikawa N., Yamazaki T., Izumi N., Uchihara M. Incidence and clinical course of major depression in patients with chronic hepatitis type C undergoing interferon-alpha therapy: a prospective study. Gen. Hosp. Psychiatry 2003, 25:34-38.
29. Keefe B. Interferon-induced depression in hepatitis C: an update. Curr. Psychiatry Rep. 2007, 9:255-261.
30. Kraus M.R., Al-Taie O., Schäfer A., Pfersdorff M., Lesch K.P., Scheurlen M. Serotonin-1A receptor gene HTR1A variation predicts interferon-induced depression in chronic hepatitis C. Gastroenterology 2007, 132:1279-1286.
31. Kraus M.R., Schäfer A., Al-Taie O., Scheurlen M. Prophylactic SSRI during interferon alpha re-therapy in patients with chronic hepatitis C and a history of interferon-induced depression. J. Viral Hepat. 2005, 12:96-100.
32. Lavanchy D. The global burden of hepatitis C. Liver Int. 2009, 29:74-81.
33. Leutscher P.D., Lagging M., Buhl M.R., Pedersen C., Norkrans G., Langeland N., Mørch K., Färkkilä M., Hjerrild S., Hellstrand K., Bech P. Evaluation of depression as a risk factor for treatment failure in chronic hepatitis C. Hepatology 2010, 52:430-435. NORDynamIC Group.
34. Lotrich F.E., Ferrell R.E., Rabinovitz M., Pollock B.G. Risk for depression during interferon-alpha treatment is affected by the serotonin transporter polymorphism. Biol. Psychiatry 2009, 65:344-348.
35. Lotrich F.E., Loftis J.M., Ferrell R.E., Rabinovitz M., Hauser P. IL28B polymorphism is associated with both side effects and clearance of hepatitis C during interferon-alpha therapy. J. Interferon Cytokine Res. 2010, e-pub ahead of print 6 Dec 2010. 10.1089/jir.2010.0074.
36. Maes M. Depression is an inflammatory disease, but cell-mediated immune activation is the key component of depression. Prog. Neuropsychopharmacol. Biol. Psychiatry 2010, e-pub ahead of print 20 Jun 2010. 10.1016/j.pnpbp.2010.06.014.
37. Miller S.A., Dykes D.D., Polesky H.F. A simple salting out procedure for extracting DNA from human nucleated cells. Nucleic Acids Res. 1988, 16:1215.
38. Morasco B.J., Rifai M.A., Loftis J.M., Indest D.W., Moles J.K., Hauser P. A randomized trial of paroxetine to prevent interferon-alpha-induced depression in patients with hepatitis C. J. Affect. Disord. 2007, 103:83-90.
39. Musselman D.L., Lawson D.H., Gumnick J.F., Manatunga A.K., Penna S., Goodkin R.S., Greiner K., Nemeroff C.B., Miller A.H. Paroxetine for the prevention of depression induced by high-dose interferon alfa. N. Engl. J. Med. 2001, 344:961-966.
40. Myakishev M.V., Khripin Y., Hu S., Hamer D.H. High-throughput SNP genotyping by allele-specific PCR with universal energy-transfer-labeled primers. Genome Res. 2001, 11:163-169.
41. Nestadt G., Addington A., Samuels J., Liang K.Y., Bienvenu O.J., Riddle M., Grados M., Hoehn-Saric R., Cullen B. The identification of OCD-related subgroups based on comorbidity. Biol. Psychiatry 2003, 53:914-920.
42. Otsubo T., Miyaoka H., Kamijima K., Onuki M., Ishii M., Mitamura K. Depression during interferon therapy in chronic hepatitis C patients. Seishin Shinkeigaku Zasshi 1997, 99:101-127.
43. Parana R., Lyra L., Trepo C. Intravenous vitamin complexes used in sporting activities and transmission of HCV in Brazil. Am. J. Gastroenterol. 1999, 94:857-858.
44. Pierucci-Lagha A., Covault J., Bonkovsky H.L., Feinn R., Abreu C., Sterling R.K., Fontana R.J., Kranzler H.R. A functional serotonin transporter gene polymorphism and depressive effects associated with interferon-alpha treatment. Psychosomatics 2010, 51:137-148. HALT-C Trial Group.
45. Pritchard J.K., Stephens M., Donnelly P. Inference of population structure using multilocus genotype data. Genetics 2000, 155:945-959.
46. Quarantini L.C., Bressan R.A., Galvão A., Batista-Neves S., Paraná R., Miranda-Scippa A. Incidence of psychiatric side effects during pegylated interferon-alpha retreatment in nonresponder hepatitis C virus-infected patients. Liver Int. 2007, 27:1098-1102.
47. Quarantini L.C., Miranda-Scippa A., Batista-Neves S., Powell V.B., Abreu N., Abreu K.C., Moura I., Crane J., Sampaio A.S., Netto L.R., Deoliveira I.R., Paraná R., Bressan R.A., Lacerda A.L. A neuropsychological study comparing patients infected with HCV and HBV without psychiatric comorbidities. J. Med. Virol. 2009, 81:1184-1188.
48. Quarantini L.C., Miranda-Scippa A., Schinoni M.I., Sampaio A.S., Santos-Jesus R., Bressan R.A., Tatsch F., de Oliveira I., Parana R. Effect of amantadine on depressive symptoms in chronic hepatitis C patients treated with pegylated interferon: a randomized, controlled pilot study. Clin. Neuropharmacol. 2006, 29:138-143.
49. Raison C.L., Demetrashvili M., Capuron L., Miller A.H. Neuropsychiatric adverse effects of interferon-alpha: recognition and management. CNS Drugs 2005, 19:105-123.
50. Raison C.L., Woolwine B.J., Demetrashvili M.F., Borisov A.S., Weinreib R., Staab J.P., Zajecka J.M., Bruno C.J., Henderson M.A., Reinus J.F., Evans D.L., Asnis G.M., Miller A.H. Paroxetine for prevention of depressive symptoms induced by interferon-alpha and ribavirin for hepatitis C. Aliment. Pharmacol. Ther. 2007, 25:1163-1174.
51. Schaefer M., Engelbrecht M.A., Gut O., Fiebich B.L., Bauer J., Schmidt F., Grunze H., Lieb K. Interferon alpha (IFN-alpha) and psychiatric syndromes: a review. Prog. Neuropsychopharmacol. Biol. Psychiatry 2002, 26:731-746.
52. Schaefer M., Schwaiger M., Garkisch A.S., Pich M., Hinzpeter A., Uebelhack R., Heinz A., van Boemmel F., Berg T. Prevention of interferon-alpha associated depression in psychiatric risk patients with chronic hepatitis C. J. Hepatol. 2005, 42:793-798.
53. Shriver M.D., Mei R., Parra E.J., Sonpar V., Halder I., Tishkoff S.A., Schurr T.G., Zhadanov S.I., Osipova L.P., Brutsaert T.D., Friedlaender J., Jorde L.B., Watkins W.S., Bamshad M.J., Gutierrez G., Loi H., Matsuzaki H., Kittles R.A., Argyropoulos G., Fernandez J.R., Akey J.M., Jones K.W. Large-scale SNP analysis reveals clustered and continuous patterns of human genetic variation. Hum. Genomics 2005, 2:81-89.
54. Su K.P., Huang S.Y., Peng C.Y., Lai H.C., Huang C.L., Chen Y.C., Aitchison K.J., Pariante C.M. Phospholipase A2 and cyclooxygenase 2 genes influence the risk of interferon-alpha-induced depression by regulating polyunsaturated fatty acids levels. Biol. Psychiatry 2010, 67:550-557.
55. The International HapMap Project. Nature 2003, 426:789-796. The International HapMap Consortium.
56. Vignau J., Karila L., Costisella O., Canva V. Hepatitis C, interferon α and depression: main physiopathologic hypothesis. Encephale 2005, 31:349-357.
57. Wichers M., Maes M. The psychoneuroimmuno-pathophysiology of cytokine induced depression in humans. Int. J. Neuropsychopharmacol. 2002, 5:375-388.
58. Organization World.Health. International Classification of Diseases (ICD-10) 1991, Geneva, World Health Organization. 10th ed.
59. Yoshida K., Alagbe O., Wang X., Woolwine B., Thornbury M., Raison C.L., Miller A.H. Promoter polymorphisms of the interferon-alpha receptor gene and development of Interferon-induced depressive symptoms in patients with chronic hepatitis C: preliminary findings. Neuropsychobiology 2005, 52:55-61.